mFOLFIRINOX as First-Line Chemotherapy in Treating Chinese Patients With Metastatic Pancreatic Cancer

Inclusion Criteria: * Patients have provided a signed Informed Consent Form * ECOG performance status of 0-1 * BMI ≥ 18.5 * Age: 18-65 years old * Histologically confirmed diagnosis of metastatic pancreatic cancer * No prior palliative chemotherapy * Measurable disease in at least 1 diameter by CT scan or MRI as per RECIST 1.1 criteria * Life expectancy ≥ 3 months * Patient has adequate bone marrow and organ function * Absolute Neutrophil Count (ANC) ≥ 2.0 x 109/L * Platelets ≥ 90 x 109/L * Hemoglobin ≥ 90 g/L * Patient has adequate liver function * AST and ALT not more than 2.5 times ULN (not more than 5.0 times ULN if there is liver metastasis) * Serum bilirubin ≤ 1.2 x ULN * Creatinine ≤ 1.25 times ULN * Good compliance Exclusion Criteria: * Pregnant or lactating women * Brain metastasis or only with bone metastasis. * Patients with severe gastrointestinal hemorrhage which need frequent blood transfusions. * Refuse to take appropriate contraceptive measures (including male patients). * Allergic to Oxaliplatin, Irinotecan, Leucovorin or 5-Fluorouracil. * Severe systemic disease out of control such as unstable or uncompensated respiratory, cardiac, liver, renal diseases. * Patient has a concurrent malignancy or has a malignancy within 5 years of study enrollment, (with the exception of non-melanoma skin cancer or cervical carcinoma in situ). * Psychiatric illness that would prevent the patient from giving informed consent. * Patient is concurrently using other antineoplastic agent * Patient has used investigational antineoplastic agent within 4 weeks prior to entry. * Known HIV-positivity. * No history of chronic diarrhea, nausea or vomit. * No ≥ grade 2 sensory peripheral neuropathy. * A history of transmural myocardial infarction (within 6 months prior to entry), congestive heart failure, and unstable angina. * Infectious disease or inflammation with body temperature ≥ 38 ℃.